Compare CLIR & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | GBIO |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 36.3M |
| IPO Year | 2012 | 2020 |
| Metric | CLIR | GBIO |
|---|---|---|
| Price | $0.58 | $5.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.00 | ★ $8.88 |
| AVG Volume (30 Days) | 115.2K | ★ 133.1K |
| Earning Date | 11-14-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,153,000.00 | ★ $15,270,000.00 |
| Revenue This Year | $13.13 | N/A |
| Revenue Next Year | $143.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $3.00 |
| 52 Week High | $1.12 | $8.40 |
| Indicator | CLIR | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 39.79 |
| Support Level | $0.55 | $5.47 |
| Resistance Level | $0.70 | $5.77 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 22.58 | 0.00 |
ClearSign Technologies Corp is engaged in providing solutions to some of the pressing productivity, energy efficiency, and pollution problems affecting the energy, oil, and gas production, boiler, and processing industries. It believes that its patented ClearSign Core technology can enhance the performance of combustion systems in a broad range of markets, including the energy (upstream oil production and downstream refining), institutional, commercial, and industrial boiler, chemical, and petrochemical industries. The company offers products that include process burners, boiler burners, flares, and ClearSign Eye.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.